Connection

JASON KIMATA to Anti-HIV Agents

This is a "connection" page, showing publications JASON KIMATA has written about Anti-HIV Agents.
Connection Strength

1.217
  1. Variable antiviral activity of islatravir against M184I/V mutant HIV-1 selected during antiretroviral therapy. J Antimicrob Chemother. 2024 02 01; 79(2):370-374.
    View in: PubMed
    Score: 0.657
  2. Localized inflammasome inhibition mitigates foreign body response to subcutaneous long-acting antiretroviral therapy for HIV. J Control Release. 2026 Feb 10; 390:114559.
    View in: PubMed
    Score: 0.187
  3. Antiviral potency of long-acting islatravir subdermal implant in SHIV-infected macaques. J Control Release. 2024 02; 366:18-27.
    View in: PubMed
    Score: 0.163
  4. Long-acting refillable nanofluidic implant confers protection against SHIV infection in nonhuman primates. Sci Transl Med. 2023 06 28; 15(702):eadg2887.
    View in: PubMed
    Score: 0.157
  5. Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J Virol. 2007 Nov; 81(22):12145-55.
    View in: PubMed
    Score: 0.053
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.